Úplné zobrazení záznamu

Toto je statický export z katalogu ze dne 23.01.2021. Zobrazit aktuální podobu v katalogu.

Bibliografická citace

.
0 (hodnocen0 x )
EB
EB
ONLINE
Cham : Springer International Publishing : Imprint: Springer, 2017
1 online zdroj
Externí odkaz    Plný text PDF 
   * Návod pro vzdálený přístup 


ISBN 978-3-319-70142-4 (e-kniha)
ISBN 9783319701417 (print)
Resistance to Targeted Anti-Cancer Therapeutics, ISSN 2196-5501 ; 16
Printed edition: ISBN 9783319701417
Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target? -- Resistance to HER2-targeted therapy -- Endocrine Resistance and Breast Cancer Stem Cells – The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes -- EGFR Resistance -- Targeting FGFR for the treatment of breast cancer -- Targeted Therapies in Breast Cancer -- Future paradigm of breast cancer resistance and treatment.
We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.  ..
001474116

Zvolte formát: Standardní formát Katalogizační záznam Zkrácený záznam S textovými návěštími S kódy polí MARC